Desmetz Caroline, Maudelonde Thierry, Mangé Alain, Solassol Jerome
CHU Montpellier, Laboratoire de Biologie Cellulaire et Hormonale, Hôpital Arnaud de Villeneuve, 371 Avenue du Doyen Giraud, Montpellier, F-34295, France.
Expert Rev Proteomics. 2009 Aug;6(4):377-86. doi: 10.1586/epr.09.56.
Biomarkers that show high sensitivity and specificity are needed for the early diagnosis and prognosis of cancer. An immune response to cancer is elicited in humans, as demonstrated, in part, by the identification of autoantibodies against a number of tumor-associated antigen (TAAs) in sera from patients with different types of cancer. Identification of TAAs and their cognate autoantibodies is a promising strategy for the discovery of relevant biomarkers. During the past few years, three proteomic approaches, including serological identification of antigens by recombinant expression cloning (SEREX), serological proteome analysis (SERPA) and, more recently, protein microarrays, have been the dominant strategies used to identify TAAs and their cognate autoantibodies. In this review, we aim to describe the advantages, drawbacks and recent improvements of these approaches for the study of humoral responses. Finally, we discuss the definition of autoantibody signatures to improve sensitivity for the development of clinically relevant tests.
癌症的早期诊断和预后需要高灵敏度和特异性的生物标志物。人体会对癌症产生免疫反应，部分证据是在不同类型癌症患者的血清中鉴定出了针对多种肿瘤相关抗原（TAA）的自身抗体。鉴定TAA及其对应的自身抗体是发现相关生物标志物的一种有前景的策略。在过去几年中，三种蛋白质组学方法，包括通过重组表达克隆进行抗原的血清学鉴定（SEREX）、血清蛋白质组分析（SERPA）以及最近的蛋白质微阵列，一直是用于鉴定TAA及其对应自身抗体的主要策略。在本综述中，我们旨在描述这些方法在研究体液免疫反应方面的优点、缺点和近期改进。最后，我们讨论自身抗体特征的定义，以提高开发临床相关检测方法的灵敏度。
